PharmaCyte Biotech Releases Presentation to Oncologists and Interviews from 2017 ASCO Meeting Event
July 06 2017 - 9:00AM
PharmaCyte Biotech, Inc. (OTCQB:PMCB), a clinical stage
biotechnology company focused on developing cellular therapies for
cancer and diabetes using its signature live-cell encapsulation
technology, Cell-in-a-Box®, today announced the release of 3 videos
from the company’s presentation and discussion with oncologists who
attended this year’s annual meeting of the American Society of
Clinical Oncology (ASCO) in Chicago. The videos consist of a
presentation made to a group of oncologists who have expressed an
interest in participating in PharmaCyte’s pivotal clinical trial in
locally advanced, inoperable and non-metastatic pancreatic cancer
(LAPC). They also include interviews with PharmaCyte’s Chief
Operating Officer, Dr. Gerald W. Crabtree, and the Chairman of
PharmaCyte’s Medical and Scientific Advisory Board, Dr. Matthias
Löhr.
The videos can be viewed at:
www.PharmaCyte.com/Media
The Chief Executive Officer of PharmaCyte,
Kenneth L. Waggoner, commented, “We hope our shareholders and the
investment community will find these videos informative and useful.
They explain how our platform technology for pancreatic cancer
works and how we intend to use that technology to treat LAPC. They
also illustrate where we are in the life-cycle of our development
of an effective cellular therapy for pancreatic cancer with no
treatment related side effects.”
About PharmaCyte Biotech
PharmaCyte Biotech is a clinical stage
biotechnology company developing cellular therapies for cancer and
diabetes based upon a proprietary cellulose-based live cell
encapsulation technology known as “Cell-in-a-Box®.” This technology
will be used as a platform upon which cellular therapies for
several types of cancer and diabetes are being developed.
PharmaCyte’s therapy for pancreatic cancer
involves encapsulating genetically engineered human cells that
convert an inactive chemotherapy drug into its active or
“cancer-killing” form. These encapsulated cells are implanted in
the blood supply as close to the patient’s cancerous tumor as
possible. Once implanted, a chemotherapy drug that is normally
activated in the liver (ifosfamide) is given at one-third the
normal dose. The ifosfamide is carried by the circulatory system to
where the encapsulated cells have been implanted. When the
ifosfamide flows through the encapsulated cells, they act as a
“bio-artificial liver” and activate the chemotherapy drug at the
site of the cancer. This “targeted chemotherapy” has proven
effective and safe to use in past clinical trials and results in no
treatment related side effects.
PharmaCyte’s cellular therapy for Type 1
diabetes and insulin-dependent Type 2 diabetes involves
encapsulating a human cell line that has been genetically
engineered to produce, store and release insulin in response to the
levels of blood sugar in the human body. The encapsulation will be
done using the Cell-in-a-Box® technology. Once the encapsulated
cells are implanted in a diabetic patient, they will function as a
“bio-artificial pancreas” for purposes of insulin production.
Safe Harbor
This press release contains forward-looking
statements, which are generally statements that are not historical
facts. Forward-looking statements can be identified by the words
"expects," "anticipates," "believes," "intends," "estimates,"
"plans," "will," "outlook" and similar expressions. Forward-looking
statements are based on management's current plans, estimates,
assumptions and projections, and speak only as of the date they are
made. We undertake no obligation to update any forward-looking
statement because of new information or future events, except as
otherwise required by law. Forward-looking statements involve
inherent risks and uncertainties, most of which are difficult to
predict and are generally beyond our control. Actual results or
outcomes may differ materially from those implied by the
forward-looking statements due to the impact of numerous risk
factors, many of which are discussed in more detail in our Annual
Report on Form 10-K and our other reports filed with the Securities
and Exchange Commission.
More information about PharmaCyte Biotech can be
found at www.PharmaCyte.com. Information may also be obtained by
contacting PharmaCyte’s Investor Relations Department.
Contact:
Investor Relations:
PharmaCyte Biotech, Inc.
Investor Relations Department
Telephone: 917.595.2856
Email: Info@PharmaCyte.com